Based on the premise of aberrant EGFR and PI3K/mTOR signaling in lung cancer [4, 6], we investigated the antiproliferative activity of the dual PI3K/mTOR inhibitor BEZ235 in 12 NSCLC cell lines: 6 expressing wild-type EGFR and 6 expressing EGFR with activating mutations, including exon 19 deletions, and L858R and T790 M point mutations. Here, MTOR is linked to lung carcinoma.